| 1 |
34000725 | Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. | 2021 |
1 |
| 2 |
30190369 | A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. | 2019 Jan 1 |
2 |
| 3 |
31799203 | Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. | 2019 Nov |
1 |
| 4 |
30395717 | Systemic therapy for hepatocellular carcinoma: beyond sorafenib. | 2018 Oct |
1 |
| 5 |
26441378 | Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. | 2016 Jun |
1 |
| 6 |
27299940 | Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. | 2016 May |
2 |